Global Survey Reveals People Want More Investment And Faster Access To New
INDIANAPOLIS, Jan. 30, 2013
INDIANAPOLIS, Jan. 30, 2013 /PRNewswire/ -- The public is generally satisfied
with cancer research progress over the past 20 years. However, they believe it
takes too long for new cancer medicines to reach patients and that their
countries invest too little in fighting cancer. Most fear that the current
economic crisis will slow cancer research progress. This is according to the
PACE Cancer Perception Index: A Six-Nation, Public Opinion Survey of Cancer
Knowledge and Attitudes, released today in advance of World Cancer Day, which
is recognized on February 4, 2013.
To view the multimedia assets associated with this release, please click:
This year, World Cancer Day focuses on "dispelling damaging myths and
misconceptions about cancer."^i The PACE Cancer Perception Index—commissioned
by Lilly Oncology and conducted by GfK, one of the world's leading research
companies—studied knowledge and attitudes about cancer treatment and care, the
health care system and patient involvement. The survey polled 4,341
individuals, including the general population (3,009), cancer patients (663)
and caregivers (669), from August 28 to October 4, 2012. Survey participants
were from six countries: the United States, France, Germany, Italy, Japan and
the United Kingdom.^*
Public's Cancer IQ Rising, but Myths Persist
The survey found clear understanding on several key aspects of cancer. A near
majority does not think a cancer diagnosis is a death sentence; the U.S. is
most optimistic (65 percent strongly disagree or disagree). Indeed, while
cancer remains a global health crisis—with more than a 70 percent increase in
worldwide incidence and mortality expected between 2008 and 2030^ii—many
cancers have shifted now from an acute to a more chronic disease, and some
cancers now are curable.^iii
At the same time, however, significant myths about cancer persist. For
example, more than four out of 10 people worldwide believe that cancer is a
single disease when in fact it is more than 200 different diseases with many
different biologic, genetic and environmental origins.^iv Taking a dim view of
the pharmaceutical industry, six in 10 of the respondents believe
pharmaceutical companies are more interested in treating cancer than curing
"That, too, is a myth," said Newton F. Crenshaw, vice president, Lilly
Oncology. "But it points to some big challenges that we have as an industry:
to educate people on our motives, what we do and how we work, and also to step
up, work as partners with health care payers, policymakers and patients, and
demonstrate our value."
Public Recognizes Cancer Progress, but Wants Faster Results
Nearly six in 10 surveyed say that they are satisfied with the progress made
in the fight against cancer over the past 20 years. However, in every country
but France, a majority or near majority thinks its country invests too little
in fighting the disease.
Strong majorities say it takes too long for new cancer medicines to reach
patients. In all countries surveyed except Japan, most state that progress in
cancer research will be slowed as a result of the poor economy.
"Patients are aware of the magnitude of cancer innovation," said J. Gordon
McVie, M.D., senior consultant to the European Institute of Oncology in Milan
and founding editor of ecancer.org. "But they're also frustrated that we—the
doctors and scientists—are not moving fast enough. And one of the problems is
that the clinical trials arena is cluttered with unnecessary obstacles. We
have to reform the drug development process."
High Interest in Clinical Trial Participation, Sharing Medical Records
The public expresses willingness to be part of an improved clinical trial and
drug development system. For example, more than 70 percent of the general
public says that patients need more opportunities to participate in clinical
trials. Today, overall clinical trial participation typically does not exceed
five percent of cancer patients.^v
Nearly nine in 10 respondents would agree to share medical records for the
improvement of cancer research and treatment. Still, sizable minorities report
concerns about potential misuse of data.
PACE (Patient Access to Cancer care Excellence), a Lilly Oncology initiative,
commissioned the survey. PACE is an emerging global network of collaborations
between industry and other sectors intended to improve public policies that
determine the accessibility, speed and value of progress against cancer. The
PACE network includes a Global Council of internationally renowned patient
advocacy, medical, policy, scientific and health care industry leaders.
According to Crenshaw, "We're seeing progress in cancer medicine and care
through countless innovations that add up to sizeable victories for patients.
Still, current economic pressures threaten this progress and place our
society's larger developments against cancer at risk."
PACE Global Council participant, Nancy Davenport-Ennis agrees.
Davenport-Ennis, a cancer survivor and founder and CEO of the National Patient
Advocate Foundation and the Patient Advocate Foundation said, "We cannot
ignore the fragility of the economic climate against which cancer research is
being conducted. To ensure that cancer continues to be a public health
priority, we need to better understand what makes cancer treatments valuable
and to involve patients more in making those determinations."
PACE Cancer Perception Index Research Methodology^**
The PACE Cancer Perception Index was fielded in France, Germany, Italy, Japan,
the UK and the U.S. National representative samples of the general population
ages 18 and over were used for the survey, deploying a random digit dial (RDD)
telephone method. The sample comprises approximately 70 percent landline
respondents and 30 percent cell phone respondents in each country in order to
account for the fact that some households only have cell phones. A total of
3,009 respondents were interviewed, with approximately 500 respondents per
country. All interviews were conducted by native language speakers of each
country, calling from a central interviewing facility in London, UK. The
sampling error is +/-1.9 percentage points for the six-county total sample,
and +/- 4.6 to +/- 5.0 percentage points for individual countries.
For the purpose of comparison, cancer patients and cancer patient caregivers
were also interviewed. A total of 663 cancer patients and 669 cancer
caregivers were interviewed, with approximately 100 from each group per
country in France, Germany, Italy, Japan, and the UK, and 150 from each group
in the U.S. Qualified respondents were selected from online panels and
interviewed online. The sample source for these two groups was primarily uSamp
for all countries; in Germany, Survey Sampling Inc. (SSI) was also used; and
in Japan, three other sample sources – AIP, Toluna and SSI – were also used.
The sample frame represents a broad mix of age, cancer type and stage but may
not represent the universe of cancer patients or their caregivers.
Created by Lilly Oncology as a global collaboration spanning diverse sectors,
PACE exists to encourage public policies and health care decisions that speed
the development of new medicines, assure cancer treatments respond to the
needs and qualities of individual patients, and improve patient access to the
most effective cancer medicines. PACE has been launched in six
countries—France, Germany, Italy, Japan, United Kingdom and the United
States—and is engaging key oncology stakeholders in each: patients, advocacy,
payers, policymakers, providers, the public, researchers and politicians. To
learn more about PACE and the PACE Cancer Perception Index, please visit
About Lilly Oncology
For more than four decades, Lilly Oncology, a division of Eli Lilly and
Company, has been dedicated to delivering innovative solutions that improve
the care of people living with cancer.Because no two cancer patients are
alike, Lilly Oncology is committed to developing novel treatment approaches.
To learn more about Lilly's commitment to cancer, please visit
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides
answers—through medicines and information—for some of the world's most urgent
GfK Roper Public Affairs & Corporate Communications, a division of GfK Custom
Research North America, specializes in customized public affairs and public
opinion polling, media and corporate communications research, and corporate
reputation measurement in the U.S. and globally.The division serves as the
official polling partner of the Associated Press conducting the AP-GfK Poll
(www.ap-gfkpoll.com).To find out more, visit www.gfk.comor follow GfK on
^* Unless otherwise specified, reported percentages refer to the general
^**Percentages not totaling 100%: For tabulation purposes, percentage points
are rounded off to the nearest whole number. As a result, percentages may
total slightly higher or lower than 100%.
^i World Cancer Day, "Cancer Myths Get the Facts,"
http://www.worldcancerday.org. Accessed December 9, 2012.
^ii Cancer Research UK, Cancer Stats Key Facts Cancer Worldwide,
Accessed January 11, 2013.
^iii National Coalition for Cancer Survivorship, "The Power of Hope,"
http://www.canceradvocacy.org/resources/hopeful/. Accessed December 11, 2012.
^iv Cancer Research UK, "Can cancer be prevented?",
Accessed January 11, 2013.
^v American Cancer Society, "Clinical Trials: What You Need to Know,"
Accessed January 3, 2013.
SOURCE Lilly Oncology
Contact: Corina Ramers-Verhoeven, Lilly, +31 30 6025 828 (office), +31 6 1500
6046 (mobile), email@example.com; or Dennis da Costa, TogoRun,
+1-212-453-2461 (office), +1-914-645-7553 (mobile), firstname.lastname@example.org
Press spacebar to pause and continue. Press esc to stop.